Articles tagged with Cerebrospinal Fluid
Researchers detect misfolded alpha-synuclein aggregates in cerebrospinal fluid to diagnose Parkinson's disease. The Protein Misfolding Cyclic Amplification technology detects small amounts of the protein, correlating with disease severity.
Researchers propose a novel storage system using pre-cut filter paper to store dried cerebrospinal fluid samples. The method was tested on 132 samples, showing high accuracy in detecting Japanese encephalitis virus antibodies.
Researchers develop new method to visualize intrathecal drug delivery using SPECT-CT imaging, revealing dynamics of cerebrospinal fluid movement and injection location. This technique may help optimize therapeutic options for neurological disorders.
Changes in key biomarkers of Alzheimer's disease during midlife may help identify those who will develop dementia years later. The study found that drops in amyloid beta 42 levels among cognitively normal participants are linked to the appearance of plaques in brain scans years later.
Researchers found a network of lymphatic vessels in the meningeal linings of the brain, directly connected to systemic lymphatic networks. This discovery raises new questions about fundamental brain functions and mechanisms of brain diseases.
A portable ultrasound device has been developed to diagnose bacterial meningitis in babies, replacing painful and time-consuming lumbar punctures. The device uses high-resolution imaging and algorithms to detect cellularity in cerebrospinal fluid, indicating infection within seconds.
A global research team led by Case Western Reserve scientist discovered a genetic dysfunction connected to hydrocephalus, illustrating how one error can contribute to excessive cerebrospinal fluid. The study found that Dvl genes regulate the placement and alignment of cilia in ependymal cells, essential for efficient fluid movement.
A study published in JAMA Neurology found that inosine treatment increases blood and cerebrospinal fluid urate levels in early Parkinson disease patients, suggesting a potential strategy to slow disability progression. The treatment was also shown to be safe and tolerable, with minimal serious adverse events.
Measuring changes in proteins in people with amyotrophic lateral sclerosis (ALS) may better predict disease progression, according to scientists at Penn State College of Medicine. Biomarkers from plasma and cerebrospinal fluid identified as useful in predicting disease duration.
Researchers analyzed cerebrospinal fluid biomarkers in patients with early-stage Parkinson's disease (PD) and healthy controls. Lower levels of Alzheimer's beta-1-42 and tau proteins were found in PD patients, associated with motor severity. The study suggests that these biomarkers have prognostic potential for early-stage PD.
A study found that decreased Aß42 and increased phosphorylated tau181 levels in spinal fluid are linked to reduced default mode network integrity. This association suggests that these biomarkers could be used to detect Alzheimer's disease pathology before symptoms appear.
A new study has identified genetic markers that may signal individuals at increased risk of developing Alzheimer's disease. The research found mutations in certain genes influencing protein accumulations in the brain and spinal fluid, which can lead to cognitive decline.
Researchers have identified two molecules that can predict which stroke patients are at risk of severe long-term disability. The study found elevated levels of endothelin converting enzyme-1 (ECE-1) and big endothelin-1 (BigET-1) in SAH patients who suffered significant disability.
Researchers found that ApoE4 gene variant affects brain function in healthy older women, causing changes characteristic of Alzheimer's disease, but has little impact on men. The study suggests a gender distinction in Alzheimer's risk, with implications for risk assessment and experimental avenues for understanding the disease.
Research suggests that cerebrospinal fluid biomarkers can identify individuals at high risk for Alzheimer's disease up to 5-10 years before symptoms appear. Studies found reduced Aβ42 and elevated T-tau and P-tau levels in patients with mild cognitive impairment who later developed Alzheimer's.
Researchers identified a signature of three biomarkers in cerebrospinal fluid that can correctly classify patients with Alzheimer's disease. The study suggests that these biomarkers can detect the pathogenic process of Alzheimer's disease at an early stage, potentially leading to earlier diagnosis and treatment.
A new study finds that X-ray-guided spinal tap procedures fail in about 60% of young infant cases and cause bleeding in 25% of infant cases. For patients over 80, the risk of bleeding doubles, but can be reduced by inserting the needle in the middle of the lower back.
Researchers identified a genetic variation associated with an earlier age of onset in Alzheimer's disease, which affects the brain's tau protein levels. The study suggests that these variations lead to higher tau levels in cerebrospinal fluid and earlier cognitive problems once amyloid plaques form.
A study of 14 Swedish amateur boxers found higher levels of certain chemicals in their cerebrospinal fluid indicating injuries to neurons and astroglia after a bout. The findings suggest that amateur boxing is associated with acute neuronal and astroglial injury, warranting further investigation for medical counseling of athletes.
Research found that middle-aged adults with a genetic risk factor for Alzheimer's develop lower levels of A42 protein in their spinal fluid. This could provide an early clue to the development of Alzheimer's, allowing for potential prevention and treatment strategies.
Researchers at Johns Hopkins Medicine have identified a new potential biomarker for multiple sclerosis, a protein fragment called 12.5 kDa cystatin found in cerebrospinal fluid, which may help diagnose the disease and monitor treatment efficacy.
A new study has identified a potential early warning system for Alzheimer's disease in patients with mild cognitive impairment. After 4-5 years of follow-up, researchers found that 42% of patients developed Alzheimer's disease and 15% developed other types of dementia.
Research found moderate hyperinsulinemia increases CNS inflammatory markers, linking insulin resistance to AD risk. Insulin-induced inflammation may contribute to AD pathology in nondiabetic adults with obesity, impaired glucose tolerance, and hypertension.
Scientists at Northwestern University have developed a new diagnostic test for Alzheimer's disease using bio-bar-code amplification technology. The test can detect miniscule amounts of a toxic protein in human cerebrospinal fluid, which may be responsible for early neurological deterioration.
According to the study, the nasal endoscopic approach was successful in treating cerebrospinal fluid rhinorrhea, with 92% of patients experiencing long-term success. The procedure involves using small cameras and monitors to operate with minimal trauma, reducing the risk of complications.
A study published at the Endocrine Society meeting found elevated cortisol levels in cerebrospinal fluid of child-bearing-aged women with functional hypothalamic amenorrhea (FHA), a condition affecting 5% of reproductive-age women. Cortisol levels were higher than those in circulating blood, suggesting stress impacts more than fertility.
Researchers have developed a novel diagnostic technique to directly detect prions in the cerebrospinal fluid, which is easily accessible for diagnostic purposes. This breakthrough method uses dual-color scanning for intensely fluorescent targets to identify single prion particles with high sensitivity.
Scientists discovered that p-glycoprotein and a similar protein collaborate to limit drug traffic through the brain. This finding could lead to improved treatment of diseases like AIDS, depression, cancer, and more.
Research reveals that the AIDS virus in cerebrospinal fluid evolves independently of the virus in the blood, leading to two genetically distinct forms. This finding suggests that drugs effective against HIV-1 in blood may not be effective in the central nervous system, and vice versa.